SLC2A3 and glioma: In this sense, the signaling pathway EGFRvII/PI3K/AKT promotes a glycolytic phenotype (Figure 2) in glioma cells by increasing the expression and membrane translocation of glucose transporters 1 and 3 (GLUT1 and GLUT3) [36,37,38] and the phosphorylation and activation of glycolytic enzymes such as hexokinase2 (HX2) [39,40], phosphofructokinase1 (PFK1) [41], phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB4,-3) [42,43], and pyruvate dehydrogenase kinase 1 (PDHK1) [44].